Gains in the fight against acid aspiration lung injury

May 02, 2006

Boston, MA -- Doctors are gaining new leverage in the fight against lung injury caused by acid reflux. The paper by Bonnans et al., "Lipoxin A4 regulates bronchial epithelial cell responses to acid injury," appears in the April issue of The American Journal of Pathology and is accompanied by a commentary.

The most familiar symptoms of acid reflux include heartburn and acid regurgitation, but in some patients, acid reflux harms more than the gastrointestinal tract -- it also injures the respiratory tract. Acid aspiration into the lungs damages the epithelial barrier and initiates acute inflammation, resulting in asthma exacerbation, chronic cough, and in the most severe cases, acute respiratory distress syndrome (ARDS), a life-threatening condition. Current management involves supportive therapies: airway maintenance, supplemental oxygen, and fluid therapy.

Because treatment of acid-induced lung injury is lacking, investigators are examining how the body heals itself from such insults in the hopes of harnessing the same mechanisms for improved medical therapies. Recently, the cellular inflammatory regulators COX-2 and LXA4 have been identified in the resolution of acid-induced lung injury in a mouse model. To determine further how COX-2 and LXA4 work at the cellular/molecular level, Dr. Bruce Levy and colleagues are exploring the resolution of acid-induced injury of the epithelial barrier of the lungs.

Using a cell culture system that replicates the air-cell interface of the lungs, Dr. Levy's group applied acid directly to the surface of the cell layer, inducing injury and death of the top layer of cells, which were shed within 2 hours. Remarkably, the layer was mostly restored within 6 hours. But how did this restoration occur?

By 2 hours following injury, the researchers found increased expression of COX-2 and the LXA4 receptor (ALX), which relied, in part, on COX-2 derived products, such as prostaglandin E2. LXA4, known to aid resolution of injury in vivo, induced proliferation of basal airway epithelial cells and reduced release of the inflammatory cytokine IL-6 in the culture system. In addition, LXA4 further prevents acute inflammation by blocking experimental transmigration of neutrophils into the damaged region. Combined, these events promote restoration of the damaged layer of cells without the added injury that can occur from excessive neutrophil and epithelial cell inflammatory responses.

These data demonstrate the importance of the anti-inflammatory function of LXA4 and its receptors (ALX) in the respiratory tract's ability to heal following acid-aspiration-induced lung injury. The capacity to enhance LXA4 signaling therapeutically may allow faster resolution of such lung injury in patients with severe disease, providing a potential new treatment in the struggle against acid-induced lung diseases, including ARDS.

Finally, this new model of acid aspiration lung injury accurately imitates in vivo cell death and shedding as well as recovery, thus providing researchers a means of testing new treatment strategies for hastening resolution of acid-induced damage.
-end-
This work was supported in part by grants from the National Institutes of Health and fellowships from La Fondation de la Recherche Medicale, Pfizer, and the Uehara Memorial Research Foundation.

This work involved collaborators at Brigham and Women's Hospital and Harvard Medical School, Boston, MA, and Washington University School of Medicine, St. Louis, MO.

Bonnans C, Fukunaga K, Levy MA, Levy BD: Lipoxin A4 regulates bronchial epithelial cell responses to acid injury. Am J Pathol 2006 168:1064-1072

Commentary: Wallace JL: Commonality of defensive roles of COX-2 in the lung and gut. Am J Pathol 2006 168:1060-1063

For press copies of the articles, please contact Dr. Audra Cox at 301-634-7409 or the Journal Editorial Office at 301-634-7959.

For more information on Dr. Bruce D. Levy, please contact Lori J. Shanks, Media Relations Coordinator at Brigham and Women's Hospital: Phone 617.534.1604; Fax 617.534.1610; Pager 617.732.6660 #33566; Email: LJShanks@partners.org.

The American Journal of Pathology, the official journal of the American Society for Investigative Pathology (ASIP), seeks to publish high-quality original papers on the cellular and molecular mechanisms of disease. The editors accept manuscripts which report important findings on disease pathogenesis or basic biological mechanisms that relate to disease, without preference for a specific method of analysis. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, biological, animal, chemical and immunological approaches in conjunction with morphology.

American Journal of Pathology

Related Lung Injury Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

Study shows heating in vaping device as cause for lung injury
Early results of an experimental vaping study have shown significant lung injury from E-cigarette (eC) devices with nickel-chromium alloy heating elements.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Perceived harm of e-cigarettes vs cigarettes after outbreak of vaping-associated lung injury
This survey study looked at perceptions of the harms of electronic cigarettes compared to regular cigarettes among current smokers in England before and after the US outbreak of vaping-associated lung injury in 2019.

Characteristics of adolescents, adults with e-cigarette or vaping product use-associated lung injury
Following an outbreak of electronic cigarette or vaping product use-associated lung injury (EVALI) linked to hospitalizations and deaths, this  study used data reported to the Centers for Disease Control and Prevention to compare demographic and clinical characteristics, along with substance use behaviors, between adolescents and adults with EVALI.

Lung injury in COVID-19 is not high altitude pulmonary edema
A group of researchers with experience in treating high altitude pulmonary edema (HAPE) have written to correct the misconception in medical social media forums and elsewhere that the lung injury seen in COVID-19 is not like typical acute respiratory distress syndrome (ARDS) and is instead like HAPE.

Types of vaping products used by hospitalized patients with severe lung injury
This report describes the kinds of vaping products used by and the clinical characteristics of patients hospitalized in California last year with e-cigarette or vaping-associated lung injury.

Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease
The authors determined that tumor-derived ANGPTL2 stimulates lung epithelial cells, which is essential for primary tumor-induced neutrophil recruitment in lung and subsequent pre-metastatic niche formation.

Read More: Lung Injury News and Lung Injury Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.